Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for inhibiting liver fibroblast proliferation, preparation method and application thereof

A technology of fibroblasts and composition, applied in the field of medicine, can solve problems such as lack of clinical treatment means

Inactive Publication Date: 2016-08-31
马修尧
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, some anti-hepatic fibrosis treatments have appeared successively, including chemical drugs, biological agents, traditional Chinese medicine and gene therapy, etc., but the ideal clinical treatment methods are still lacking. The main links are: reduce liver damage; inhibit the activation of stellate cells, reduce the production of extracellular matrix; regulate the disorder of cytokines, promote the apoptosis of activated hepatic stellate cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for inhibiting liver fibroblast proliferation, preparation method and application thereof
  • Medicine composition for inhibiting liver fibroblast proliferation, preparation method and application thereof
  • Medicine composition for inhibiting liver fibroblast proliferation, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of compound composition tablet involved in the present invention:

[0016] Take 7 grams of compound Cyclomarinone and 3 grams of Maristachones D, add 190 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0017] Embodiment 2: the preparation of compound composition capsule involved in the present invention:

[0018] Get 7 grams of compound Cyclomarinone and 3 grams of Maristachones D, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0020] Experimental Example 1: Using the MTT method to evaluate the inhibitory effect of the compound composition of the present invention on liver fibrosis

[0021] 1. Method: NIH / 3T3 cell line was purchased from the cell bank of Shanghai Institute of Cellular Sciences, Chinese Academy of Sciences, cited from ATCC (American Type Culture Collection). The subconfluent NIH / 3T3 cells in the logarithmic growth phase were digested with 0.25% trypsin, washed, centrifuged, and made into 1×10 cells with DMEM culture medium (containing 10% FCS). 4 cell / ml cell suspension, the survival rate identified by trypan blue staining is greater than 95%, add 100ul per well to a 96-well plate, and store at 37°C, 5% CO 2 After cultivating for 24h synchronous treatment, the supernatant was discarded, and DMEM culture fluid (containing 10 %FCS) 200ul, cultivated for 48h, added MTT solution to each well and incubated for 4h. Discard the culture medium, add 150ulDMSO, shake for 10 minutes to dissolv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines and particularly provides a medicine composition for inhibiting liver fibroblast proliferation. The medicine composition includes a compound I and a compound II as active components, wherein the mass percentages of the compound I and the compound II are respectively 70% and 30%. The compound I is Cyclomarinone while the compound II is Maristachones D. Pharmacological test proves that the medicine composition can significantly inhibit generation and development of liver fibrosis, can be used for preparing medicines resisting liver fibrosis and preventing and treating liver cirrhosis. The medicine composition belongs to a novel framework type, has strong inhibition activity on the liver fibroblast proliferation, has outstanding substantive features and has significant improvement when being applied for resisting the liver fibroblast proliferation.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for inhibiting proliferation of liver fibroblasts, a preparation method and application thereof. Background technique [0002] Liver fibrosis is a dynamic process from chronic liver injury to liver cirrhosis. In the past 20 years, the research on liver fibrosis has made great progress, and it has been confirmed that liver fibrosis and liver cirrhosis are reversible to a certain extent. In recent years, some anti-hepatic fibrosis treatments have appeared successively, including chemical drugs, biological agents, traditional Chinese medicine and gene therapy, etc., but the ideal clinical treatment methods are still lacking. The main steps are: reduce liver damage; inhibit the activation of stellate cells, reduce the production of extracellular matrix; regulate the disorder of cytokines, and promote the apoptosis of activated hepatic stellate cells. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/343A61P1/16A61K31/122
CPCA61K31/122A61K31/343A61K2300/00
Inventor 马修尧
Owner 马修尧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com